Alexander Bukreyev, PhD
Professor

Departments of Pathology and Microbiology & Immunology

Phone: (409) 772-2829
Lab: (409) 772-2831
Email: alexander.bukreyev@utmb.edu

The Bukreyev Lab

Alexander Bukreyev, PhD

  • Our Lab focuses on investigation of the mechanisms of the high pathogenicity of viruses Ebola, Marburg and Lassa and development of vaccines and antibody treatments against these viruses. More recently we also started work with respiratory syncytial virus (RSV), Crimean-Congo hemorrhagic fever virus and hantaviruses Andes and Sin Nombre.

    Our research includes, but not limited to, the following specific topics:

    • Investigation of dysregulated immune response to Ebola virus at epigenetic level.
    • Development of vaccines and investigation of the mechanisms of their protective effects.
    • In-depth characterization of antibody responses to viral infections in humans.
    • Development of therapeutic human monoclonal antibody treatments and investigation of the mechanisms of their protective effects.

    To get insight into these scientific topics, we are using molecular tools, including reverse genetics (i.e. development of genetically modified filoviruses from the DNA-copies of their genomes and use of mini-genomes), epigenetic methods (ATAC-seq, cut-and-run), single-cell sequencing, immunological tools such as multi-parameter flow cytometry, human immune cells and animal models. Our research includes experiments in BSL-2, BSL-3 and BSL-4 labs of the Galveston National Laboratory. Our research is supported by grants from NIH and DoD and by contracts.

    Our collaborators include Dr. Mariano Garcia-Blanco (University of Virginia), Dr. James Crowe, Jr. (Vanderbilt University), Dr. Andrea Carfi (Moderna), Dr. Stuart Sealfon (Mount Sinai School of Medicine), Dr. Erica Ollmann Saphire (La Jolla Institute for Immunology), Dr. Thomas Geisbert (UTMB), and other groups.
  • MS Pyatigorsk Pharmaceutical Institute, Pyatigorsk, Russia. Pharmacy 1984
    PhD State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia. Molecular Biology 1993
    • Convener of the Filoviruses Workshop, 41th Annual Meeting of American Society for Virology, University of Wisconsin, Madison, Wisconsin. July 18, 2022.
    • Co-chair of the workshop “Interference with Host Defense”, 40th Annual Meeting of American Society for Virology (virtual), July 23, 2021.
    • American Society for Virology Program Planning Committee, 2020-2023.
    • Member of the WHO Expert Group on COVID-19 Animal Model, Invited on May 6, 2020.
    • Organizer and convener of the workshop “Immune correlates of protection for vaccines against biothreat viruses” at the 2020 American Society for Microbiology Biothreats meeting. Arlington, Virginia, January 28, 2020.
    • Co-chair of the workshop “Infectious and Non-infectious Diseases / Emerging & Re-emerging Diseases” at the Vaccines Research and Development conference. Crowne Plaza Boston, November 12, 2019.
    • NIH Vaccines Against Microbial Diseases (VMD) Study Section, Member, July 1, 2017 – June 30, 2021.
    • Researcher of the Year, Department of Pathology, University of Texas Medical Branch at Galveston. May 6, 2015.
    • Member of the Organizing Committee of the 6th International Symposium on Filoviruses, Galveston, Texas, March 30 – April 2, 2014.
    • Convener of the Viral Epidemiology Workshop, 32th Annual Meeting of American Society for Virology, The Pennsylvania State University, University Park, Pennsylvania. July 20-24, 2013.
    • Convener of the Emerging Viruses Workshop, 31th Annual Meeting of American Society for Virology, University of Wisconsin, Madison, Wisconsin. July 21-25, 2012.
    • Member of the Filoviridae Study Group of the International Committee on Taxonomy of Viruses, 2012 – 2014, 2015 – 2017, 2017 – 2020.
    • Member of Global Viral Network, 2011-present.
    • Convener of the Filoviruses Workshop, 30th Annual Meeting of American Society for Virology, University of Minnesota, Minneapolis, Minnesota. July 16, 2011.
    • American Society for Virology Program Planning Committee, 2010-2013.
    • Convener of the Filoviruses Workshop, 29th Annual Meeting of American Society for Virology, Montana State University, Bozeman, Montana. July 17, 2010.
    • Convener of the Vaccine and Viral Vectors III Workshop, 28th Annual Meeting of American Society for Virology, University of British Columbia, Vancouver, Canada. July 14, 2009.
    • National Institute of Allergy and Infectious Diseases Performance Award in Recognition of Special Achievement in Support of the Mission of the National Institute of Allergy and Infectious Diseases. 2006; 2007; 2008 (two awards); 2009 (two awards).
    • The National Institutes of Health Merit Award in Recognition of Outstanding Contributions and Efforts in Support of NIAID Mission. 2005.
    • National Institute of Allergy and Infectious Diseases Staff Recognition Awards in Recognition and Appreciation of Special Achievement. 2001; 2002; 2003; 2004; 2005.
    • The National Institute of Health Fellows Award for Research Excellence. 2000 (competitive).
    • Special Act of Service Award, National Institute of Allergy and Infectious Diseases in Recognition and Appreciation of Special Achievement. 1999.
    • Personal Russian State Scholarship for Young Outstanding Scientists. 1994-1996. Awarded by the Presidium of the Russian Academy of Sciences. 1994.

  • Professional Societies

    • International Society for Vaccines, Member, 2020 – present
    • American Society for Microbiology, Contributing Member, 2019 – present.
    • American Society for Virology, Full Member, 1996 - present.
    • The Keck Center for Quantitative Biomedical Science Training, Keck Faculty Affiliate. 2015 – present.
    • NIH Virology Interest Group, 1997 - 2010.

    Editor or member of editorial board

    • Journal of Virology 2016 – 2024
    • Vaccine 2014 – present
    • Expert Review of Vaccines 2010 – present
    • Journal of Bioterrorism & Biodefense 2010 – present
    • PLOS Pathogens: Guest Associate Editor (2018), Academic Editor 2019 - present
    • PLOS Neglected Tropical Diseases: Guest Editor (2018), Academic Editor 2019 – present
    • Pathogens 2020 – present
    • Viruses 2022 – present
    • Frontiers in Immunology – Associate Editor 2023 – present

  • Selected publications in peer-reviewed journals

    N. M. Lubaki, P. Ilinykh, C. Pietzsch, B. Tigabu, A. N. Freiberg, R. A. Koup, and A. Bukreyev (2013). The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87(13):7471-7485. The article was chosen for UTMB press release on 05/02/13.

    P. A. Ilinykh, B. Tigabu, A. Ivanov, T. Ammosova,  Y. Obukhov, T. Garron, N. Kumari, D. Kovalskyy, M. O. Platonov, V. S. Naumchik, A. N. Freiberg, S. Nekhai, and A. Bukreyev (2014). Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 and its targeting for the inhibition of viral transcription. J Biol. Chem. 289(33): 22723-38.

    A. I. Flyak, P. A. Ilinykh, C. D. Murin, T. Garron, X. Shen, M. L. Fusco, T. Hashiguchi, Z. A. Bornholdt, J. C. Slaughter, G. Sapparapu, T. G. Ksiazek, A. B. Ward, E. O. Saphire, A. Bukreyev*, and J. E. Crowe, Jr.* (2015) Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160(5): 893-903. The article was chosen for UTMB and the Vanderbilt University press releases on 5/26/2015. *Co-senior authors.

    P. Ilinykh, M. Lubaki, S. Widen, L. A. Renn, T. C. Theisen, N. R. Rabin, T. Wood, and A. Bukreyev (2015) Different temporal effects of Ebola virus VP35 and VP24 on global gene expression in human dendritic cells. J. Virol. 90(15):7567-83.

    M. Meyer, T. Garron, N. M. Lubaki, C. E. Mire, K. A. Fenton, C. Klages, G. G. Olinger, T. W. Geisbert, P. L. Collins, and A. Bukreyev (2015) Aerosolized Ebola vaccine protects primates and elicits lung-resident T-cell responses. J. Clin. Invest. 125(8): 3241-55. The article was chosen for UTMB press release and NIH press release on 7/13/2015.

    A. I. Flyak, X. Shen, C. D. Murin, H. L. Turner, M. L. Fusco, R. Lampley, N. Kose, P. A. Ilinykh, N. Kuzmina, A. Branchizio, H. King, L. Brown, C. Bryan, E. Davidson, B. J. Doranz, J. C. Slaughter, G. Sapparapu, C. Klages, T. G. Ksiazek, E. O. Saphire, A. B. Ward, A. Bukreyev,* and J. E. Crowe, Jr.* (2016) Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection. Cell 164(3): 392-405. The article was chosen for UTMB and the Vanderbilt University press releases on 1/21/2016, and was highlighted in Nature 529, 440. *Co-corresponding authors.

    P. A. Ilinykh, X. Shen, A. I. Flyak, N. Kuzmina, T. G. Ksiazek, J. E. Crowe, Jr., and A. Bukreyev (2016) Chimeric filoviruses for identification and characterization of monoclonal antibodies. J. Virol. 90(8): 3890-901.

    A. Rialdi, L. Campisi, N. Zhao, A. C. Lagda, C. Pietzsch, J. S. Ho, L. Martinez-Gil, R. Fenouil, X. Chen, M. Edwards, G. Metreveli, S. Jordan, Z. Peralta, C. Muniz-Fontela, N. Bouvier, M. Merad, J. Jin, M. Weirauch, S. Heinz, C. Benner, H. van Bakel, C. Basler, A. Garcia-Sastre, A. Bukreyev, and I. Marazzi. (2016) Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science. 352 (6289): aad7993. The article was chosen for Icahn School of Medicine at Mount Sinai press releases on 4/28/2016.

    N. M. Lubaki*, P. Younan*, R. I. Santos, M. Meyer, M. Iampietro, R. A. Koup, and A. Bukreyev. (2016). The Ebola interferon inhibiting domains attenuate and dysregulate cell-mediated immune responses. PLOS Pathogens 21(12):e1006031. The article was chosen for UTMB press releases on 12/01/2016. *Co-lead authors.

    I. V. Kuzmin, T. M. Schwarz, P. A. Ilinykh, I. Jordan, T. G. Ksiazek, R. Sachidanandam, C. F. Basler, and A. Bukreyev (2017). Innate immune response of bat and human cells to filoviruses: commonalities and distinctions. J. Virol. 91(8):e02471-16.

    P. Luthra, S. Aguirre, M. T. Sanchez, B. C. Yen, C. A. Pietzsch, B. Tigabu, L. Morlock, A. Garcia-Sastre, A. Sesma, N. Williams, A. Bukreyev, D. W. Leung, and C. Basler. (2017). Topoisomerase II inhibitors induce DNA Damage dependent interferon responses circumventing Ebola virus immune evasion. mBio. 8(2) e00368-17.

    P. Younan, P. Ramanathan, J. Graber, F. Gusovsky, and A. Bukreyev. (2017). The TLR4 antagonist Eritoran protects mice from lethal filovirus challenge. mBio 8(2) e00226-17.

    M. Iampietro*, P. Younan*, A. Nishida, M. Dutta, N. M. Lubaki, R. I. Santos, R. A. Koup, M. G. Katze, and A. Bukreyev. (2017). Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLOS Pathogens 13(5):e1006397. The article was chosen for UTMB press releases on 05/24/2017. *Co-lead authors.

    P. Younan, M. Iampietro, A. Nishida, P. Ramanathan, R. I. Santos, M. Dutta, N. M. Lubaki, R. A. Koup, M. G. Katze, and A. Bukreyev. (2017). Ebola binding to Tim-1 on T-Lymphocytes induces a cytokine storm. mBio 8(5) e00845-17. The article was chosen for American Society of Microbiology and UTMB press releases on 09/26/2017.

    L. B. King, M. L. Fusco, A. I. Flyak, P. A. Ilinykh, K. Huang, B. Gunn, R. N. Kirchdoerfer., K. M. Hastie, A. Sangha, J. Meiler, G. Alter, A. Bukreyev, J. E. Crowe, Jr., and E. Ollmann Saphire. (2018) Therapeutic human monoclonal antibody MR191against Marburg virus targets a conserved site to block receptor binding. Cell Host & Microbe 23(1):101-109.

    M. Meyer, E. Huang, O. Yuzhakov, P. Ramanathan, G. Ciaramella, and A. Bukreyev. (2019) Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217(2):451-455.

    M. Meyer, E. Huang, O. Yuzhakov, P. Ramanathan, G. Ciaramella, and A. Bukreyev (2018) Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217(2):451-455.

    P. Younan, M. Iampietro and A. Bukreyev (2018). Disabling of lymphocyte immune response by Ebola Virus. PLOS Pathogens 14(4):e1006932.

    E. O. Saphire, S. L. Schendel, M. L. Fusco, K. Gangavarapu, B. M. Gunn, A. Z. Wec, P. J. Halfmann, J. M. Brannan, A. S. Herbert, X. Qio et al. (2018). Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174(4):938-952.

    A. I. Flyak, N. Kuzmina, C. D. Murin, C. Bryan, E. Davidson, P. Gilchuk, C. P. Gulka, P. A. Ilinykh, X. Shen, P. Ramanathan, K. Huang, H. Turner, M. L. Fusco, R. Lampley, N. Kose, H. King, G. Sapparapu, B. J. Doranz, T. G. Ksiazek, D. W. Wright, E. Ollmann Saphire, A. B. Ward, A. Bukreyev*, and J. E. Crowe*, Jr. (2018). Neutralizing antibodies from human survivors target a conserved site in the ebolavirus glycoprotein HR2/MPER regions. *Co-corresponding author. Nature Microbiology 3(6):670-677.

    P. Gilchuk, N. Kuzmina, P. A. Ilinykh, K. Huang, B. M. Gunn, A. Bryan, E. Davidson, B. J. Doranz, H. L. Turner, M. L. Fusco, M. S. Bramble, N. A. Hoff, E. Binshtein, N. Kose, A. I. Flyak,, R. Flinko, C. Orlandi, R. Carnahan, E. H. Parrish, A. M. Sevy, R. G. Bombardi, P. K. Singh, P. Mukadi, J. J. Muyembe-Tamfum, M. D. Ohi, E. Ollmann Saphire , G. K. Lewis, G. Alter, A. B. Ward, A. W. Rimoin, A. Bukreyev*, and J. E. Crowe, Jr*. (2018). Multifunctional pan-ebolavirus antibodies recognize a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49(2):363-374. *Co-corresponding author. The article was chosen for NIAID press releases on 07/17/2018.

    M. Meyer, A. Yoshida, P. Ramanathan, E. Ollmann Saphire, P. Collins, J. E. Crowe Jr., S. Samal and A. Bukreyev (2018). Antibody repertoires to the same Ebola vaccine antigen are differentially affected by vaccine vectors. Cell Reports 24: 1816-1829.

    N. A. Kuzmina, P. Younan, P. Gilchuk, R. I. Santos, A. I. Flyak, P. A. Ilinykh, K. Huang,   N. M. Lubaki, P. Ramanathan, J. E. Crowe, Jr. and A. Bukreyev (2018). Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Reports 24: 1802-1815.

    M. Iampietro, R. I. Santos, N. M. Lubaki and A. Bukreyev (2018). Ebola Virus Shed GP Triggers Differentiation, Infection and Death of Monocytes Through TLR4 Activation. J. Infect. Dis. 218(Suppl. 5): S327-S334.

    T. Ammosova, C. A. Pietzsch, Y. Saygideğer, A. Ilatovsky, X. Lin, A. Ivanov, N. Kumari, M. Jerebtsova, A. Kulkarni, M. Petukhov, A. Üren, A. Bukreyev* and Sergei Nekhai* (2018). Protein phosphatase-1-targeting small molecule C31 inhibits Ebola virus replication. J. Infect. Dis. 218 (Suppl. 5): S627-S635. *Co-corresponding author.

    P. A. Ilinykh, J. Graber, N. A. Kuzmina, K. Huang, T. G. Ksiazek, J. E. Crowe, Jr. and A. Bukreyev (2018). Ebolavirus chimerization for the development of a mouse model for screening of Bundibugyo-specific antibodies. J. Infect. Dis. 218 (Suppl. 5): S418-S422.

    P. A. Ilinykh, R. I. Santos, B. M. Gunn, N. A. Kuzmina, X. Shen, K. Huang, P. Gilchuk, A. I. Flyak, P. Younan, G. Alter, J. E. Crowe, Jr., and A. Bukreyev (2018). Assymetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. PLOS Pathogens 14(8):e1007204.

    P. Younan, M. Iampietro, R. I. Santos, P. Ramanathan, V. L. Popov and A. Bukreyev (2018). Role of TMEM16F in the incorporation phosphatidylserine into budding ebolavirus virions. J. Infect. Dis. 218 (Suppl. 5): S335-S345.

    P. Younan, M. Iampietro, R. I. Santos, P. Ramanathan, V. L. Popov and A. Bukreyev (2018). Disruption of phosphatidylserine synthesis or trafficking reduces infectivity of Ebola virus. J. Infect. Dis. 218 (Suppl. 5): S475-S485.

    B. Tigabu, P. Ramanathan, A. Ivanov, X. Lin, P. A. Ilinykh, C. S. Parry, A. N. Freiberg, S. Nekhai and A. Bukreyev (2018). Phosphorylated VP30 of Marburg Virus is a Repressor of Transcription. J. Virol. 92(21):e00426-18.

    M. Meyer, D. C. Malherbe and A. Bukreyev (2018). Can Ebola virus vaccines have universal correlates of protection? Trends in Microbiology 27(1):8-16.

    J. Fang, C. Pietzsch, P. Ramanathan, R. I. Santos, P. A. Ilinykh, M. A. Garcia-Blanco, A. Bukreyev and S. S. Bradrick (2018). Staufen1 interacts with multiple components of the Ebola virus ribonucleoprotein and enhances viral RNA synthesis. mBio 9(5): e01771-18.

     

    J. B. Kimble, D. C. Malherbe, M. Meyer, B. M. Gunn, M. M. Karim, P. A. Ilinykh, M. Iampietro, K. S. Mohamed, S. Negi, P. Gilchuk, K. Huang, Y I. Wolf, W. Braun, J. E. Crowe Jr., G. Alter and A. Bukreyev (2019). Antibody-mediated protective mechanisms induced by a trivalent parainfluenza-vectored ebolavirus vaccine. J. Virol. 93(4): e01845-18.

    B. R. West, A. Z. Wec, C. L. Moyer, M. L. Fusco, P. A. Ilinykh, K. Huang, A. S. Wirchnianski, R. M. James, A. S. Herbert, S. Hui, E. Goodwin, K. A. Howell, S. Kailasan, M. J. Aman, L. M. Walker, J. M. Dye, A. Bukreyev, K. Chandran and E. Ollmann Saphire (2019). Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody. Nature Structural & Molecular Biology 26(3):204-212.

    L. B. King, B. R. West, C. L. Moyer, P. Gilchuk, A. Flyak, P. A. Ilinykh, R. Bombardi, S. Hui, K. Huang, A. Bukreyev, J. E. Crowe, Jr. and E. Ollmann Saphire (2019). Cross-reactive, neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nature Communications 10 (1):1788.

    P. Younan, R. I. Santos, P. Ramanathan, M. Iampietro, A. Nishida, M. Dutta, T. Ammosova, M. Meyer, M. G. Katze, V. L. Popov, S. Nekhai and A. Bukreyev (2019). Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection. PLOS Pathogens 15(10):e1008068. This article was chosen for UTMB Press Release on October 24, 2019.

    A. Ivanov, P. Ramanathan, C. Parry, P. A. Ilinykh, X. Lin, Y. Obukhov, T. Ammosova, G. K Amarasinghe, A. Bukreyev* and S. Nekhai* (2019). Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription Cellular and Molecular Life Sciences 77(13):2579-2603. *Co-corresponding author.

    P. Gilchuk, D. Murin, J.C. Milligan, R.W. Cross, C.E. Mire, P.A. Ilinykh, K. Huang, N. Kuzmina, P.X. Altman, S. Hui, B.M. Gunn, A.L. Bryan, E. Davidson, B.J. Doranz, H.L. Turner, T. Alkutkar, R. Flinko, C. Orlandi, R. Carnahan, R. Nargi, R.G. Bombardi, M.E. Vodzak, S. Li, A. Okoli, M. Ibeawuchi, B. Ohiaeri, G.K. Lewis, G. Alter, A. Bukreyev, E. Ollmann Saphire, T.W. Geisbert, A.B. Ward, J.E. Crowe Jr. (2020). Analysis of therapeutic antibody cocktail reveals determinants of cooperative and broad Ebola virus neutralization. Immunity 52(2):388-403.

    A. N. Prasad, A. J. Ronk, S. G. Widen, T. G. Wood, C. F. Basler, A. Bukreyev (2020).  Ebola virus produces discrete small noncoding RNAs independently of the host microRNA pathway which lack RNA interference activity in bat and human cells. Journal of Virology 94(6): e01441-19.

    P. A. Ilinykh, K. Huang , R. I. Santos, P. Gilchuk, B. M. Gunn, M. M. Karim, J. Liang, M. E. Fouch, E. Davidson, D. V. Parekh, J. B. Kimble, C. A. Pietzsch, M. Meyer, N. A. Kuzmina, L. Zeitlin, E. O. Saphire, G. Alter, J. E. Crowe* and A. Bukreyev* (2020). Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host & Microbe 27(6):976-991.e11. This article was chosen for UTMB Press Release on April 21, 2020. *Co-corresponding author.

    Z. J. Whitfield, A. N. Prasad, A. J. Ronk, I. V. Kuzmin, Philipp A. Ilinykh, R. Andino* and A. Bukreyev* (2020). Species-specific evolution of Ebola virus during replication in human and bat cells. Cell Reports 32(7):108028. This article was chosen for UTMB Press Release on August 18, 2020. *Co-corresponding author.

    D. C. Malherbe, A. Domi, M. J. Hauser, M. Meyer, B. M. Gunn, G. Alter, A. Bukreyev* and F. Guirakhoo* (2020). Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus challenge. NPJ Vaccines 5:78. *Co-corresponding author.

    N. G. Bozhanova, A. K. Sangha, A. M. Sevy, P. Gilchuk, P. A. Ilinykh, A. Bukreyev, J. E. Crowe, Jr. and J. Meiler (2020). Discovery of Marburg Virus Neutralizing Antibodies from Virus-Naïve Human Antibody Variable Gene Repertoires Using Large-scale Structural Predictions. Proc. Natl. Acad. Sci. USA 117(49):31142-31148.

    C. Atyeo, M. D. Slein, S. Fischinger, J. Burke, A. Schӓfer, S. R. Leist, N. A. Kuzmina, A. Honko, R. Johnson6, N. Storm, M. Bernett, P. Tong, T. Zuo, J. Lin, A. Zuiani, C. Linde, T. Suscovich, D. Wesemann, A. Griffiths, J. R. Desjarlais, B. D. Juelg, J. Goutsmit, A. Bukreyev, R. Baric and G. Alter (2020). Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight 6(1):e143129.

    C. Atyeo, M. D. Slein, S. Fischinger, J. Burke, A. Schӓfer, S. R. Leist, N. A. Kuzmina, A. Honko, R. Johnson6, N. Storm, M. Bernett, P. Tong, T. Zuo, J. Lin, A. Zuiani, C. Linde, T. Suscovich, D. Wesemann, A. Griffiths, J. R. Desjarlais, B. D. Juelg, J. Goutsmit, A. Bukreyev, R. Baric and G. Alter (2020). Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight 11;6(1):e143129.

    A. Ilinykh and A. Bukreyev (2021). Antibody responses to filovirus infections in humans: Protective or not? Lancet Inf. Dis. 21(11):e348-e355.

    D. Kurup, D. C. Malherbe, C. Wirblich, R. Lambert, A. J. Ronk, L. Z. Diba, A. Bukreyev* and M. J. Schnell* (2021). Inactivated rabies vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLOS Pathogens 17(3): e1009383. *Co-corresponding authors.

    B. M. Gunn, R. Lu, M. D. Slein, P. A. Ilinykh, K. Huang, C. Atyeo, S. L. Schendel, J. Kim, C. Cain, V. Roy, T. J. Suscovich, A. Takada, P. J. Halfmann, Y. Kawaoka, M. G. Pauthner, M. Momo, A. Goba, L. Kanneh, K. G. Andersen, J. S. Schieffelin, D. Grant, R. F. Garry, E. Ollmann Saphire*, A. Bukreyev* and G. Alter* (2021). A Fc-Engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 54(4):815-828.e5. *Co-corresponding authors.  

    C. D. Murin, P. Gilchuk, T. Alkutkar, J. F. Bruhn, L. E. Williamson, J. Copps, P. A. Ilinykh, K. Huang, N. Kuzmina, X. Shen, A. L. Bryan, E. Davidson, B. J. Doranz, A. I. Flyak, A. Bukreyev, J. E. Crowe, Jr. and A. B. Ward (2021). Convergence of a common solution to broad ebolavirus neutralization by glycan cap directed human antibodies. Cell Rep. 35(2):108984.

    T. B. Engdahl, N. A. Kuzmina, A. J. Ronk, C. E. Mire, M. A. Hyde, N. Kose, M. D. Josleyn, R. E. Sutton, A. Mehta, R. M. Wolters, N. M. Lloyd, F. R. Valdivieso, T. G. Ksiazek, J. W. Hooper, A. Bukreyev* and J. E. Crowe, Jr.* (2021). Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Rep. 35(5): 109086. *Co-corresponding authors.

    K. B. Hoehn, P. Ramanathan,  A. Unterman, T. S. Sumida, H. Asashima, D. A. Hafler, N. Kaminski, C. S. Dela Cruz, S. C. Sealfon, A. Bukreyev and S. H. Kleinstein (2021). Cutting Edge: Distinct B cell repertoires characterize patients with mild and severe COVID-19. J. Immunol. 206(12):2785-2790.

    D. C. Malherbe, D. Kurup, C. Wirblich, A. J. Ronk, C. Mire, N. Kuzmina, N. Shaik, S. Periasamy, M. A. Hyde, J. M. Williams, P.-Y. Shi, M. J. Schnell* and A. Bukreyev*. (2021). A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. NPJ Vaccines 6(1):91. *Co-corresponding authors. 

    I. Ramos, C. W. Goforth, A. Soares-Schanoski, D. L Weir, E. C Samuels, S. Phogat, M. Meyer, K. Huang, C. A Pietzsch, Y. Ge, B. L Pike, J. Regeimbal, M. P Simons, M. Termini, S. Vangeti, N. Marjanovic, S. Lizewski, R. Lizewski, M.-C. George, V. D Nair, G. R Smith, W. Mao, M. Chikina, C. C. Broder, E. Laing, A. Bukreyev, S. C Sealfon and A. G Letizia (2021). Antibody responses to SARS-CoV-2 following an outbreak among Marine recruits with asymptomatic or mild infection. Front. Immunol. 12:681586.

    M. Meyer, B. M. Gunn, D. C. Malherbe, K. Gangavarapu, A. Yoshida, C. Pietzsch, N. A. Kuzmina, E. Ollmann Saphire, P. L. Collins, J. E. Crowe Jr, J. J. Zhu, M. A. Suchard, D. L. Brining, C. E. Mire, R. W. Cross, J. B. Geisbert, S. K. Samal, K. G. Andersen, G. Alter, T. W. Geisbert and A. Bukreyev (2021). Ebola vaccine-induced protection in non-human primates correlates with antibody specificity and Fc-mediated effects. Sci. Transl. Med. 13(602):eabg6128. This article was chosen for UTMB Press Release on July 14, 2021.

    P. Gilchuk, A. Guthals, S. R. Bonissone, J. B. Shaw, P. A Ilinykh, K. Huang, R. G Bombardi, J. L., A. Grinyo, E. Davidson, E. C. Chen, B. Gunn, G. Alter, E. Ollmann Saphire, B. J Doranz, A. Bukreyev, L. Zeitlin, N. Castellana and J. E Crowe (2021). Proteo-genomic analysis identifies two major sites of vulnerability on ebolavirus glycoprotein for neutralizing antibodies in convalescent human plasma. Front. Immunol. 12:706757.

    A. G. Letizia, Y. Ge, S. Vangeti, C. Goforth, D. L. Weir, N. A. Kuzmina, C. A. Balinsky, H. W. Chen, D. Ewing, A. Soares-Schanoski, M. C. George, W. D. Graham, F. Jones, P. Bharaj, R. A. Lizewski, S. E. Lizewski, J. Marayag, N. Marjanovic, C. M. Miller, S. Mofsowitz, V. D. Nair, E. Nunez, D. M. Parent, C. K. Porter, E. Santa Ana, M. Schilling, D. Stadlbauer, V. A. Sugiharto, M. Termini, P. Sun, R. P. Tracy, F. Krammer, A. Bukreyev, I. Ramos and S. C. Sealfon (2021). SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Medicine 9(7):712-720.

    M. Meyer, Y. Wang, D. Edwards, G. R. Smith, A. B. Rubenstein, P. Ramanathan, C. E. Mire, C. Pietzsch, X. Chen, Y. Ge, W. S. Cheng, C. Henry, A. Woods, L. Z. Ma, G. B. E. Stewart-Jones, K. W. Bock, M. Minai, B. M. Nagata, S. Periasamy, P. Y. Shi, B. S. Graham, I. N. Moore, I. Ramos, O. G. Troyanskaya, E. Zaslavsky, A. Carfi*, S. C. Sealfon* and A. Bukreyev* (2021). Attenuated activation of pulmonary immune cells in mRNA-1273 vaccinated hamsters after SARS-CoV-2 infection. J. Clin. Invest. 131(20):148036.

    P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B., Geisbert, R. H. Carnahan, R. S. Nargi, R. E Sutton, N. Suryadevara1, S. J. Zost, R. G. Bombardi, A. Bukreyev, T. W. Geisbert, A. B. Ward and J. E. Crowe, Jr. (2021). Protective pan-ebolavirus combination therapy 1 by two multifunctional human antibodies. Cell 184(22):5593-5607.

    P. Maisonnasse, Y. Aldon, A. Marc, R. Marlin, N. Dereuddre-Bosquet, N. Kuzmina, A. W. Freyn, J. L. Snitselaar, A. Gonçalves, T. G. Caniels, J. A. Burger, M. Poniman, I. Bontjer, V. Chesnais, S. Diry, A. Iershov, A. J. Ronk, S. Jangra, R. Rathnasinghe, P. J. M. Brouwer, T. P. L. Bijl, J. van Schooten, M. Brinkkemper, H. Liu, M. Yuan, C. E. Mire, M. J. van Breemen, V. Contreras, T. Naninck, J. Lemaitre, N. Kahlaoui, F. Relouzat, C. Chapon, R. H. T. Fang, C. McDanal, M. Osei-Twum, N. St-Amant, L. Gagnon, D. C. Montefiori, I. A. Wilson, E. Ginoux, G. J. de Bree, A. Garcia-Sastre, M. Schotsaert, L. Coughlan, A. Bukreyev, S. van der Werf, J. Guedj, R. W. Sanders, M. J. van Gils and R. Le Grand (2021). COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nat. Commun. 12(1):6097. 

    D. F. Lake, A. J. Roeder, E. Kaleta, P. Jasbi, K. Pfeffer, C. Koelbela, S. Periasami, N. Kuzmina, A. Bukreyev, T. E. Grys, L. Wu, J. R. Mills, K. McAulay, M. Gonzalez-Moa, A. Seit-Nebi and S. Svarovsky (2021). Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2. J. Clin. Virol. 145:105024.

    I. V. Kuzmin, P. Ramanathan, C. F. Basler and A. Bukreyev (2021). Effects of overexpression of the Egyptian fruit bat innate immune genes on filovirus infections in the host cells. Frontiers in Virology 1:759655.

    J. C. Milligan, C. W. Davis, X. Yu, P. A. Ilinykh, K. Huang, P. Halfmann, R. W. Cross, V. Borisevich, K. N. Agans, J. B. Geisbert, C. Chennareddy, A. J. Goff, A. E. Piper, S. Hui, K. Shaffer, T. Buck, M. L. Heinrich, L. M. Branco, I. Crozier, M. R. Holbrook, J. H. Kuhn, Y. Kawaoka, P. J. Glass, A. Bukreyev, T. W. Geisbert, G. Worwa, R. Ahmed and E. Ollmann Saphire (2022). Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185(6):995-1007.e18.

    J. Fang, C. Pietzsch, G. Tsaprailis, G. Crynen, K. F. Cho, A. Y. Ting, A. Bukreyev*, J. Carlos de la Torre*, and E. Ollmann Saphire* (2022). Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication. Cell Reports 38(12):110544. *Co-corresponding author.

    A. Soares-Schanoski, N. Sauerwald, C. W. Goforth, S. Periasamy, D. L. Weir, S. Lizewski, R. Lizewski, Y. Ge, N. A. Kuzmina, V. D. Nair, S. Vangeti, N. Marjanovic, A. Cappuccio, W. Sze Cheng, S. Mofsowitz, C. M. Miller, X. B. Yu, M. C. George, E. Zaslavsky, A. Bukreyev, O. G. Troyanskaya, S. C. Sealfon, A. G. Letizia and I. Ramos (2022). Asymptomatic SARS-CoV-2 infection is associated with higher levels of serum IL-17C, matrix metalloproteinase 10 and fibroblast growth factors than mild symptomatic COVID-19. Frontiers in Immunol 13:821730.

    P. A. Ilinykh, S. Periasamy, K. Huang, N. A. Kuzmina, P. Ramanathan, M. N. Meyer, C. E. Mire, I. V. Kuzmin, P. Bharaj, J. R. Endsley, M. Chikina, S. C. Sealfon, S. G. Widen, M. A. Endsley and A. Bukreyev (2022). A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. NPJ Vaccines 7(1):47.

    S. van Tol, B. Kalveram, P. Ilinykh, A. Ronk, K. Huang, L. Aguilera-Aguirre, P. Bharaj, A. Hage, C. Atkins, M. Giraldo, M. Wakamiya, A. Bukreyev, A. Freiberg and R. Rajsbaum (2022). Ubiquitination of Ebola virus VP35 at lysine 309 regulates viral transcription and assembly. PLOS Pathogens 18(5):e1010532. 

    C. T. Schoeder, P. Gilchuk, A. K. Sangha, K. V. Ledwitch, D. C. Malherbe, X. Zhang, E. Binshtein, L. E. Williamson, C. E. Martina, J. Dong, E. Armstrong, R. Sutton, R. Nargi, J. Rodriguez, N. Kuzmina, B. Fiala, N. P. King, A. Bukreyev, J. E. Crowe, Jr. and J. Meiler (2022). Epitope-focused immunogen design based on the ebolavirus glycoprotein HRs-MPER region. PLOS Pathogens 18(5):e1010518.

    A. R. Schiakolas, K. J. Kramer, N. V. Johnson, S. C. Wall, N. Suryadevara, D. Wrapp, S. Periasamy, K. A. Pilewski, N. Raju, R. E. Sutton, L. M. Walker, I. Setliff, J. E. Crowe Jr., A. Bukreyev, R. H. Carnahan, J. S. McLellan and I. S. Georgiev (2022). Efficient discovery of SARS-CoV-2-neutralizing antibodies via B-cell receptor sequencing and ligand blocking. Nature Biotechnology 40(8):1270-1275.

    D. C. Malherbe, A. Domi, M. J. Hauser, C. Atyeo, S. Fischinger, M. A. Hyde, J. M. Williams, G. Alter, F. Guirakhoo, and A. Bukreyev (2022). A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection. NPJ Vaccines 7(1):83.

    J. Fang, C. Pietzsch, H. Witwit, G. Tsaprailis, G. Crynen, K. F. Cho, A. Y. Ting, A. Bukreyev, E. Ollmann Saphire and J. C. de la Torre (2022). Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host directed antivirals. Proc. Natl. Acad. Sci. USA 119(30):e2201208119.

    Y. Liu, X. Zhang, J. Liu, H. Xia, J. Zou, A. E. Muruato, S. Periasamy, C. Kurhade, J. A. Plante, N. E. Bopp, B. Kalveram, A. Bukreyev, P. Ren, T. Wang, V. D. Menachery, K. S. Plante, X. Xie, S. C. Weaver and P. Y. Shi (2022). A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun. 13(1):4337.

    M. R. Chang, L. Tomasovic, N. A. Kuzmina, A. J. Ronk, P. O. Byrne, R. Johnson, N. Storm, E. Olmedillas, Y. J. Hou, A. Schaefer, S. R. Leist, L. V. Tse, H. Ke, C. Coherd, K. Nguyen, M. Kamkaew, A. Honko, Q. Zhu, G. Alter, E. Ollmann Saphire, J. S. McLellan, A. Griffiths, R. S. Baric, A. Bukreyev and W. A. Marasco (2022). IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat. Commun. 13(1):5814.

    Y. C. Bartsch, D. Cizmeci, J. Kang, T. Zohar, S. Periasamy, N. Mehta, J. Tolboom, L. van der Fits, J. Sadoff, C. Comeaux, B. Callendret, A. Bukreyev, D. A. Lauffenburger, A. R. Bastian, and G. Alter (2022). Antibody effector functions are associated with protection from respiratory syncytial virus. Cell 185:1-14.

    E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, E. Davidson, E. Ollman Saphire, B. J. Doranz, N. Castellana, A. Bukreyev, R. H. Carnahan and J. E. Crowe Jr. (2023). Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes. bioRxiv (ahead of print)

    doi: https://doi.org/10.1101/2022.01.12.476089

    F. Guirakhoo, S. Wang, H. K. Kuo, W. J. Peng, J. H. Huang, B. S. Kuo, F. Lin, Y. J. Liu, Z. Liu, H. T. Wu, S. Ding, K. L. Hou, J. Cheng, Y. T. Yang, M. H. Jiang, M. S. Wang, T. Chen, W. G. Xia, E. Lin, C. H. Hung, H. J. Chen, Z. Shih, Y. Lin, V. Ryan, B. T. Schurter, M. M. Hu, G. Heppner, D. C. Malherbe, S. Periasamy, N. Kuzmina, C. Subramani, M. Hellerstein, T. P. Monath, A. Rumyantsev, A. Bukreyev and C. Y. Wang (2023). A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerging Microbes & Infections TEMI-2022-0864.R1 (in press). 

    S. Vangeti, S. Periasamy, P. Sun, C. Balinsky, A. Mahajan, N. Kuzmina, A. Soares-Schanoski, E. Cooper, C. Beckett, J. Marayag, A. Marrone, E. Nunez, Y. Ge, C. Porter, C. Goforth, S. Lizewski, R. Lizewski, V. Jani, V. Sugiharto, M. Schilling, X. Yu, N. Marjanovic, M. George, A. Bukreyev, S. Sealfon, A. Letizia and I. Ramos (2023). Serum Fc-mediated monocyte phagocystosis activity is stable for several months after SARS-CoV-2 asymptomatic and mildly symptomatic infection. Spectrum Journal SPECTRUM01837-22R1 (in press).

    P. J. M. Brouwer, A. Antanasijevic, A. J. Ronk, H. Muller-Krauter, Y. Watanabe, M. Claireaux, N. M. Lloyd, T. P. Bijl, H. R. Perrett, T. H. Steijaert, J. A. Burger, M. M. van Haaren, K. Sliepen, M. J. van Gils, M. Crispin, T. Strecker, A. Bukreyev, A. B. Ward and R. W. Sanders (2023). Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability. Cell Host & Microbe CHOM_2813 (in press).

    J. Mahita, B. Ha, A. Gambiez, S. L. Schendel, H. Li, K. M. Hastie, S. M. Dennison, K. Li, N. Kuzmina, S. Periasamy, A. Bukreyev, J. E. Munt, M. Osei-Twum, C. Atyeo, J. A. Overton, R. Vita, H. Guzman-Orozco, M. Mendes, M. Kojima, L. Powell, G. Alter, L. Gagnon, R. S. Baric, G. D. Tomaras, T. Germann, D. Bedinger, J. A. Greenbaum, E. Ollmann Saphire and B. Peters (2023). Coronavirus immunotherapeutic consortium database (CoVIC-DB). DATABASE DATABASE-2022-0133.R1 (in press).